AvenCell Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 58

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $36M

  • Investors
  • 12

AvenCell General Information

Description

Developer of T cell-based immunotherapies intended to support cancer treatment. The company focuses on building chimeric antigen receptor T cells for precise targeting of cancer antigens to overcome the limitations of current-generation CAR-T cell therapies with an improved therapeutic window and substantially expand the types of cancer treatable with adoptive cell therapy, including solid tumors, enabling clinical researchers to create a pipeline of autologous and allogeneic universal reprogrammable T cell products, focused initially on hard-to-treat cancers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 500 Forge Road
  • Suite 302
  • Watertown, MA 02472
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 500 Forge Road
  • Suite 302
  • Watertown, MA 02472
  • United States
+1 (617)

AvenCell Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AvenCell Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 17-Sep-2026 $36M Completed Clinical Trials - Phase 2
4. Early Stage VC 11-Sep-2025 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 18-Oct-2024 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) $65.8M $65.8M Completed Pre-Clinical Trials
1. Joint Venture 30-Jul-2021 Completed Pre-Clinical Trials
To view AvenCell’s complete valuation and funding history, request access »

AvenCell Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-2
Series B-1
Series A-2a 13,326,226 $0.000100 8% $1.65 $1.65 $1.65 9.66%
Series A-1 26,652,452 $0.000100 8% $1.65 $1.65 $1.65 19.33%
To view AvenCell’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

AvenCell Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AvenCell Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
JIC Venture Growth Investments Venture Capital Minority
Ligand Pharmaceuticals Corporation Minority
Therapy Acceleration Program (TAP) Not-For-Profit Venture Capital Minority
JVC Investment Partners Family Office Minority
Eight Roads Corporate Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

AvenCell FAQs

  • When was AvenCell founded?

    AvenCell was founded in 2021.

  • Where is AvenCell headquartered?

    AvenCell is headquartered in Watertown, MA.

  • What is the size of AvenCell?

    AvenCell has 58 total employees.

  • What industry is AvenCell in?

    AvenCell’s primary industry is Drug Discovery.

  • Is AvenCell a private or public company?

    AvenCell is a Private company.

  • What is AvenCell’s current revenue?

    The current revenue for AvenCell is .

  • How much funding has AvenCell raised over time?

    AvenCell has raised $228M.

  • Who are AvenCell’s investors?

    JIC Venture Growth Investments, Ligand Pharmaceuticals, Therapy Acceleration Program (TAP), JVC Investment Partners, and Eight Roads are 5 of 12 investors who have invested in AvenCell.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process